Illumina helps maximize biobank specimen value by connecting the underlying genetics of your samples with the vast array of phenotypic information already associated with them. The combination of sequencing and microarray technologies facilitates a wide variety of biobank studies, ranging from biomarker and drug target identification to translational research, disease association studies, pharmacogenomics research, and more.
Illumina provides a complete genomic solution for biobank sample analysis, with a seamless transition from variant discovery using next-generation sequencing (NGS) to the statistical power of large-scale genotyping with arrays. Whether you need standard microarrays, custom microarrays, or sequencing products, Illumina offers content flexibility for any application.
Illumina microarrays deliver a robust way to genotype biobank samples from multiple different sources, including blood, saliva, and buccal swabs. Microarrays offer an efficient quality control method for specimens before storage or shipping. They also enable genome-wide association studies (GWAS) and phenome-wide association studies (PheWAS), which can be used to detect variants associated with disease or identify genomic targets for drug development.
Compare key specifications of Illumina arrays recommended for biobank genotyping studies.Array Kit Selector Compare Biobank Arrays
Find whole-genome, exome, and targeted arrays featuring expert-defined content.See All Array Kits
Design fully custom genotyping arrays targeting up to 1 million markers, or customize existing arrays with newly discovered markers.Find Custom Arrays
Quantitatively interrogate methylation sites across the genome at single-nucleotide resolution.Learn More
NGS offers an unbiased method to detect very rare variants which are difficult to identify using array technology. Whole-genome or whole-exome sequencing can be used to discover new SNPs and indels to include on future genotyping arrays, while targeted resequencing enables confirmation of array results and closer investigation of genomic regions of interest. RNA sequencing enables researchers to assess how variants affect transcription and gene expression.
When sequencing of biobank samples reveals new causal variants, researchers need to validate these results on a larger scale. Custom genotyping arrays offer statistical power for screening these novel variants, either through addition of these markers to existing arrays, or through the design of fully custom arrays. Learn more about custom genotyping.
NGS and microarrays deliver the throughput, accuracy, and versatility needed for assessing the diverse aspects of complex disease biology. Learn more about complex disease genomics.
Our comprehensive NGS and array-based solutions can help researchers understand the role of genetics in disease identification, pathology, prognosis, treatment, and prevention. Learn more about translational research.
Illumina technologies support multiple cancer research applications, and can enable a deeper and more accurate analysis of a tumor’s molecular profile. Learn more about cancer genomics.
Illumina offers genomic sequencing solutions to inform the drug development process, from discovery through companion diagnostics research. Learn more about NGS for drug development.
NGS allows highly accurate, hypothesis-free analysis of pathogens. Examine variations across genomes to better understand the mechanisms that lead to infection and spread. Learn more about epidemiology.